

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Multivariable analysis of factors associated with revascularization after SCAD

Characteristic	OR (95% CI)	P value
Year of index SCAD event	0.85 (0.78, 0.93)	0.0003
Age (years)	0.96 (0.92, 1.0)	0.048
PSCAD	0.96 (0.52, 1.79)	0.905
SCAD location in LM or LAD	1.53 (0.64, 3.67)	0.340
Multiple SCAD territories	7.03 (1.8, 27.4)	0.0049


Supplemental Table 2. Discharge medications after SCAD event by time quintiles, restricted to patients with definite SCAD

Medications	Before 2013 (n=27)	2013-2016 (n=27)	2017 (n=23)	2018 (n=25)	2019 (n=22)
ASA	26 (96)	26 (96)	23 (100)	25 (100)	22 (100)
DAPT	16 (59)	17 (63)	17 (74)	20 (80)	20 (91)
Statins	12 (44)	19 (70)	18 (78)	20 (80)	19 (86)
Beta blockers	21 (78)	25 (93)	22 (96)	21 (84)	21 (96)
ACEi/ARBs	10 (37)	9 (33)	8 (35)	10 (40)	11 (50)

Supplemental Table 3. FMD screening modalities over time

Screening Modality	Before 2013 (n=39) No. (%)	2013-2016 (n=30) No. (%)	2017 (n=28) No. (%)	2018 (n=28) No. (%)	2019 (n=27) No. (%)	<i>P</i> value
Renal Ultrasound	1 (3)	2 (7)	3 (11)	6 (21)	3 (11)	0.138
Carotid Ultrasound	1 (3)	6 (20)	3 (11)	5 (18)	4 (15)	0.198
CTA/MRA Abdomen	8 (20)	9 (30)	13 (46)	12 (43)	9 (33)	0.177
CTA/MRA Neck	6 (15)	7 (23)	9 (32)	9 (32)	5 (18)	0.392
CTA/MRA Head	6 (15)	4 (13)	6 (21)	5 (18)	5 (18)	0.938

Supplemental Figure 1. Management of SCAD over time, restricted to patients with definite SCAD



Supplemental Figure 2. FMD screening rates over time, restricted to patients with ≥ 2 cardiology follow-up visits or 1 cardiology follow-up visit at ≥ 1 year after their SCAD event

